General practitioners' reasons for removing patients from their lists: postal survey in England and Wales by Pickin, M. et al.
15 Anon. The use of opioids for the treatment of chronic pain: a consensus
statement from the American Academy of Pain Medicine and the Ameri›
can Pain Society. Pain Forum 1997;6:77–9.
16 Cummings›Ajemian I. Treatment of related symptoms. In: RB Patt, ed.
Cancer pain, section III, non›pharmacological treatment and novel approaches to
management.Philadelphia: JB Lippincott, 1993.
17 Jeal W, Benfield P. Transdermal fentanyl—a review of its pharmacological
properties and therapeutic efficacy in pain control. Drugs 1997;53:
109›38.
18 Grond S, Zech D, Lehman KA, Radbruch L, Breintenbach H, Hertel D.
Transdermal fentanyl in the long›term treatment of cancer pain: a
prospective study of 50 patients with advanced cancer of the
gastrointestinal tract or the head and neck origin. Pain 1997;69:191›8.
19 Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral
morphine to transdermal fentanyl: a multicentre study in patients with
cancer pain. Pain 1996;64:527›34.
20 Donner B, Zenz M, Strumpf M, Raber M. Long›term treatment of
cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998;15:
168›75.
21 Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained release
oral morphine in cancer pain: preference, efficacy, and quality of life. J
Pain Symptom Manage 1997;13:254›61.
22 Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R.
Quality of life and cancer pain: satisfaction and side effects with transder›
mal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588›93.
23 Dellemijn, PLI, van Duijn H, Vanneste JAL. Prolonged treatment with
transdermal fentanyl in neuropathic pain. J Pain Symptom Manage
1998;16:220›9.
24 TTS›Fentanyl Multicentre Study Group. Transdermal fentanyl in cancer
pain. J Drug Dev 1994;6:93›7.
25 Zech DFJ, Grond SAU, Dauer HG, Stollenwerk B, Lehmann KA.
Transdermal fentanyl and initial dose›finding with patient›controlled
analgesia in cancer pain. A pilot study with 20 terminally ill cancer
patients. Pain 1992;50:293›301.
26 Southam MA. Transdermal fentanyl therapy: system design, pharmacoki›
netics and efficacy. Anticancer Drugs 1995;6(suppl 3):29›34.
27 Ware JE, Sherbourne CD. The MOS 36›item short›form health survey
(SF›36). I. Conceptional framework and item selection. Med Care
1992;30:473›83.
28 Koch CG. The use of non›parametric methods in the statistical analysis of
the two period change›over design. Biometrics 1972;28:577›84.
29 Watson HR, Pearce AC. Treatment allocation in clinical trials: randomisa›
tion and minimisation compared in three test cases. Pharmaceut Med
1990;4:207›12.
30 Collett B›J. Opioid tolerance: the clinical perspective. Br J Anaesth
1998;81:58›68.
31 Bruera E, Sloan P, Mount B, Scott J, Suarez›Almazar M. A randomized,
double›blind, double›dummy, crossover trial comparing the safety
and efficacy of oral sustained›release hydromorphine with immediate›
release hydromorphine in patients with cancer pain. J Clin Oncol 1996;
14:1713›7.
32 Amanzio M, Benedetti F. Neuropharmacological dissection of placebo
analgesia: expectation›activated opioid systems versus conditioning›
activated specific subsystems. J Neurosci 1999;19:484›94.
33 Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for
pain: polymorphisms, variations in expression, nociception, and opiate
responses. Proc NatlAcad Sci 1999;96:7752›5.
34 Megens AAHP, Artois K, Vermeire J, Meert T, Awouters FHL. Compari›
son of the analgesic and intestinal effects of fentanyl and morphine in
rats. J Pain Symptom Manage 1998;15:253›8.
35 McQuay HJ, Jadad AR, Carroll D, Faura C, Glynn CJ, Moore RA, et al.
Opioid sensitivity of chronic pain: a patient›controlled analgesia method.
Anaesthesia 1992;47:757–67.
36 Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is
everything—large amounts of information are needed to overcome ran›
dom effects in estimating direction and magnitude of treatment effects.
Pain 1998;78:209›16.
37 Haynes B. Can it work? Does it work? Is it worth it? BMJ 1999;319:652›3.
38 Max M. Methodological issues in the design of analgesic clinical trials. In:
Mitchell M, ed. Pain 1999—an update review. Seattle: IASP Press, 1999.
39 Tramer MR. When placebo controlled trials are essential and equivalence
trials are inadequate. BMJ 1998;317:875›80.
40 Torgerson DJ, Sibbald B. Understanding controlled trials: what is a
patient preference trial? BMJ 1998;316:360.
41 Senn S. Within›patient studies: cross›over trials and n›of›1 studies. In:
Mitchell M, ed. Pain 1999—an update review. Seattle: IASP Press, 1999.
42 Goodare H, Lockwood S. Involving patients in clinical research. BMJ
1999;319:724›5.
(Accepted 13 December 2000)
General practitioners’ reasons for removing patients from
their lists: postal survey in England and Wales
Mark Pickin, Fiona Sampson, James Munro, Jon Nicholl
The removal of patients from doctors’ lists causes con›
siderable public and political concern, with speculation
that patients are removed for inappropriate, including
financial, reasons.1 In 1999 the House of Commons
Select Committee on Public Administration noted that
little evidence was available on either the frequency of,
or the reasons for, removal of patients.2 National statis›
tics do not distinguish between patients removed after
moving out of a practice area and those removed for
other reasons. Two postal surveys have reported why
general practitioners might, in general, remove
patients,3 4 and one small study has described the
reasons doctors give for particular removals.5 We
therefore determined the current scale of, and doctors’
reasons for, removal of patients from their lists in Eng›
land and Wales.
Participants, methods, and results
In April 2000 we sent a questionnaire to 1000 general
practitioners in a random sample of practices, but to
no more than one doctor per practice. Up to two
reminders were sent to non›respondents at fortnightly
intervals.
The questionnaire asked for the number of patients
removed from the practice list in the previous six
months (for reasons other than living outside the prac›
tice area), the reasons contributing to the most recent
removal, and whether that removed patient was given a
reason. A list of suggested reasons for removal was
included (having been compiled in the light of
published opinions3 5), and respondents were asked to
indicate which of these were “primary” reasons and
which others were “contributory.”
The questionnaire also asked whether target
payment systems (for childhood immunisation and
cervical smear testing) and financial arrangements for
drug budgets and out of hours care created financial
incentives for removing patients.
Of the 1000 doctors surveyed, 14 replied that they
were not working in general practice. Of the remaining
986, 748 (76%) responded. In the previous six months
300 out of 745 practices (40% (95% confidence interval
37% to 44%)) had removed one or more patients. When
21 practices whose list size was not stated were excluded,
988 patients had been removed during this period from
a registered population of 4.6 million, (removal rate of
4.3 (4.1 to 4.6) per 10 000 patients a year).
The primary and contributory reasons given for
the most recent removal by each of these 300 practices
are shown in the table. Violent, threatening, or abusive
behaviour was given as a primary reason in 176 of
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300 removals (59% (53% to 64%)) and as a
contributory reason in a further 24 (8%). Other
primary reasons given were complaint by a patient (5
(2%) cases), non›compliance with childhood immuni›
sation (4 (1%)), and non›compliance with cervical
smear testing (2 (7%)).
In 238 of 288 (83% (78% to 87%)) most recent
removals, the practice had given the patient a reason
for the removal, either in writing (55% (157)) or in per›
son (28% (81)).
About half of general practitioners believed that
the target payment systems for childhood immunisa›
tion (370/732) and cervical smear testing (360/732)
had created financial incentives to remove patients.
Smaller, but still substantial, proportions of respond›
ents considered that financial arrangements for
practice drug budgets (295/728) and out of hours care
(321/733) also created such incentives.
Comment
General practitioners report that violent, threatening,
or abusive behaviour by patients is their most common
reason for removing a patient from their list.
Non›compliance with childhood immunisation or cer›
vical smear testing was rarely reported as a reason, and
never as the sole reason, for removal despite the
perceived financial incentives for removal.
The validity of our findings depends on doctors
being able and willing to identify and report the
number of removals and their reasons for them. If our
respondents were unaware of all removals from the
practice or were not truthful about why they removed
patients, our findings will misrepresent the situation.
Moreover, patients may have different views of the
events leading to removal, which future research
should seek to understand.
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Primary and contributory reasons given by 300 practices for most recent removal of a
patient from their list. Values are numbers (percentages) of practices citing each reason
Reason Primary Contributory
Violence, threats, or abuse 176 (59) 24 (8)
Drug or substance misuse 36 (12) 51 (17)
Inappropriate demand:
In normal hours 38 (13) 47 (16)
Out of hours 24 (8) 31 (10)
Inappropriate demand for
medication
31 (10) 54 (18)
Non›compliance with:
Appointments 38 (13) 39 (13)
Treatment 25 (8) 44 (15)
Childhood immunisation 4 (1) 5 (2)
Cervical smear testing 2 (1) 5 (2)
Deception or crime 44 (15) 26 (9)
Complaint or litigation by patient 5 (2) 14 (5)
Inappropriate sexual behaviour 7 (2) 6 (2)
Request for unconventional
treatment
3 (1) 6 (2)
Cultural differences 3 (1) 3 (1)
Request for particular kind of
general practitioner
2 (1) 4 (1)
Other 11 (4) 3 (1)
Some respondents gave more than one primary reason or more than one contributory reason per removal.
One hundred years ago
After›dinner speeches
After›dinner speaking out of the mouths of some few
practitioners becomes a science, and nothing can
better promote digestion than to set back “serenely
full” and listen to the founded periods and elaborate
impromptus of someome whose natural gifts have
been cultivated by art. Genius has been defined,
wrongly we think, as the faculty of taking pains, but
there is no doubt that whoever wishes to excel in
post›prandial oratory must adopt this course, the
absence of which caused the failure of the Vicar of
Wakefield’s family portrait. On minor occasions
anyone possessing a fluent tongue, and knowledge
and nerve, and a pinch of the Attic salt of humour will
probably speak best on the spur of the moment, but
trusting to inspiration may sometimes prove a broken
reed, and those who have to obey the orders of the
toast master when important issues are at stake may
be advised to make more or less careful preparation.
When the late Sir James Paget had to deliver an
important speech he might be met in the Regent’s
Park pacing round and round, and rehearsing his
performance; and Charles Dickens, facile princeps with
his tongue as with his pen, would walk miles over
Hampstead Heath declaiming and gesticulating when
he had to take the chair at a public dinner. On the
other hand, over›elaboration becomes a positive evil
when it leads to the production and infliction of long
dreary harangues which must be continued to their
bitter end, with scanty regard to the comfort of the
long›suffering audience.
(BMJ 1901;ii:910)
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